Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages

  Navarro Millán, Iris ^a   Sattui, Sebastian E ^a   Curtis, Jeffrey R ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

anti tumor necrosis factor discontinuation; rheumatoid arthritis; rheumatoid arthritis remission

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOTHERAPY; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POLYPHARMACY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-TUMOR NECROSIS FACTOR DISCONTINUATION; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS REMISSION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 84887992832     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.015     Document Type: Review

References (31)

1. F.C. Breedveld, M.H. Weisman, and A.F. Kavanaugh The PREMIER Study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who have not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
2. D.E. Furst, M.H. Schiff, and R.M. Fleischmann Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 30 2003 2563 2571
3. A. Kavanaugh, E.W. St. Clair, and W.J. McCune Chimeric antitumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy J Rheumatol 27 2000 841 850
4. E. Keystone, D. Heijde, and D. Mason Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthrits: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 58 2008 3319 3329
5. D.A. Ollendorf, D. Klingman, E. Hazard, and S. Ray Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population Clin Ther 31 2009 825 835
6. F. Al-Niaimi Adalimumab-induced lupus erythematosus Eur J Dermatol 31 2009 825 835
7. A.P. Cairns, M.K. Duncan, A.E. Hinder, and A.J. Taggart New onset systemic lupus erythematosus in a patient receiving entanercept for rheumatoid arthritis Ann Rheum Dis 61 2002 1031 1032
8. N. Mohan, E.T. Edwards, and T.R. Cupps Demyelination occuring during anti-tumor necrosis factor alpha therpay for inflammatory arthritis Arthritis Rheum 44 2001 2862 2869
9. T. Bongartz, A.J. Sutton, and M.J. Sweeting Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies JAMA 295 2006 2275 2285
10. G.R. Burmester, P. Mease, and B.A. Dijkmans Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases Ann Rheum Dis 12 2009 1863 1869
11. J.R. Curtis, J. Xi, and N. Patkar Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists Arthritis and rheumatism 56 2007 4226 4227
12. S. Gabriel, C. Crowson, and W. O'Fallon The epidemiology of rheumatoid arthritis in Rochester, Minnesota 1955-1985 Arthritis Rheum 1999 1999 415 420
13. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010 Arthritis Rheum 63 2011 2151 2156
14. M.A. Quinn, P.G. Conaghan, and P.J. O'Connor Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 52 2005 27 35
15. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis Rheum 52 2005 3381 3390
16. M. van den Broek, N.B. Klarenbeek, and L. Dirven Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study Ann Rheum Dis 70 2011 1389 1394
17. S.M. van der Kooij, Y.P. Goekoop-Ruiterman, and J.K. de Vries-Bouwstra Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis Ann Rheum Dis 68 2009 914 921
18. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial Ann Intern Med 146 2007 406 415
19. N.B. Klarenbeek, S.M. van der Kooij, and M. Guler-Yuksel Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study Ann Rheum Dis 70 2011 315 319
20. J.S. Smolen, P. Nash, and P. Durez Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial Lancet 381 2013 918 929
21. J. Detert, H. Bastian, and J. Listing Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study Ann Rheum Dis 72 2013 844 850
22. M. Nawata, K. Saito, S. Nakayamada, and Y. Tanaka Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission Mod Rheumatol 18 2008 460 464
23. O. Brocq, E. Millasseau, and C. Albert Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis Joint Bone Spine 76 2009 350 355
24. Y. Tanaka, T. Takeuchi, and T. Mimori Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study Ann Rheum Dis 69 2010 1286 1291
25. A. van der Maas, W. Kievit, and B.J. van den Bemt Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study Ann Rheum Dis 71 2012 1849 1854
26. M. Harigai, T. Takeuchi, and Y. Tanaka Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity Mod Rheumatol 22 2012 814 822
27. A. Kavanaugh, R.M. Fleischmann, and P. Emery Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study Ann Rheum Dis 72 2013 64 71
28. A. Kavanaugh, P. Emery, and R. Fleischmann Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial Arthritis Rheum 63 2011 65 66
29. D.T. Felson, J.S. Smolen, and G. Wells American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials Ann Rheum Dis 70 2011 404 413
30. B. Saleem, A.K. Brown, and M. Quinn Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study Ann Rheum Dis 71 2012 1316 1321
31. B. Saleem, H. Keen, and V. Goeb Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69 2010 1636 1642